Roth Capital Has Bearish Estimate for CAPR Q3 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Analysts at Roth Capital reduced their Q3 2025 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a report released on Tuesday, August 12th. Roth Capital analyst B. Pachaiyappan now anticipates that the biotechnology company will post earnings per share of ($0.66) for the quarter, down from their previous forecast of ($0.44). Roth Capital currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. Roth Capital also issued estimates for Capricor Therapeutics’ Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($2.37) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at $1.40 EPS, Q4 2026 earnings at $3.01 EPS and FY2026 earnings at $3.47 EPS.

CAPR has been the topic of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 price target on shares of Capricor Therapeutics in a research note on Friday, July 11th. HC Wainwright decreased their price target on Capricor Therapeutics from $77.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, July 11th. B. Riley initiated coverage on Capricor Therapeutics in a research note on Thursday, June 26th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.56.

Capricor Therapeutics Trading Down 6.3%

Shares of NASDAQ CAPR opened at $7.78 on Thursday. The stock has a market cap of $355.70 million, a price-to-earnings ratio of -4.74 and a beta of 0.59. Capricor Therapeutics has a 1-year low of $3.84 and a 1-year high of $23.40. The stock’s 50-day moving average is $9.29 and its 200 day moving average is $11.03.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently made changes to their positions in CAPR. Summit Investment Advisors Inc. boosted its position in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $68,000. Citizens Financial Group Inc. RI bought a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $95,000. Finally, KLP Kapitalforvaltning AS boosted its position in shares of Capricor Therapeutics by 65.2% during the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 4,300 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.